Table 5.
Baseline Characteristics of the Patients Grouped by CRP Score
| Variables | CRP≤12.75 | CRP>12.75 | P |
|---|---|---|---|
| N=35 | N=38 | ||
| Age, y | 57 (36–77) | 56.5 (31–76 | 0.629 |
| Gender (male/female) | 19/16 (54.3/45.7) | 30/8 (78.9/21.1) | 0.025 |
| Hepatitis (yes /no) | 18/17 (51.4/48.6) | 18/20 (50/45.9) | 0.729 |
| ALT, U/L, (>/≤50) | 25.7 (6.7–133.8) | 28.5 (6.5–95.4) | 0.834 |
| AST, U/L, (>/≤40) | 35 (14.5–207.7) | 35.85 (17.6–168.6) | 0.604 |
| ALB, g/L, (>/≤35) | 44.5 (33.4–50.1) | 39.05 (25.9–47.1) | <0.001 |
| TBIL, umol/L, (>/≤17.1) | 12.6 (2.6–45.3) | 10.85 (4.4–44.4) | 0.711 |
| CA19-9U/mL, (>/≤100) | 40.15 (1.2–35,704) | 217.75(1.54–9475) | 0.068 |
| Largest tumour size, cm | 8.1 (3.6–17.2) | 8.6 (5.5–15.8) | 0.32 |
| Tumor number (>1/1) | 24/11 (68.6/31.4) | 26/12 (68.4/31.6) | 0.989 |
| Macrovascular invasion (yes/no) | 18/17 (51.4/48.6) | 15/23 (39.5/60.5) | 0.305 |
| Lymph node metastasis (yes/no) | 19/16 (54.3/45.7) | 48/25 (65.8/34.2) | 0.048 |
| TNM stage (III–IV /II) | 20/15 (57.1/42.9) | 30/8 (78.9/21.1) | 0.045 |
| Best tumor response | |||
| CR | 0(0) | 0(0) | |
| PR | 8(22.9) | 2(5.3) | |
| SD | 19(54.3) | 18(47.4) | |
| PD | 8(22.9) | 18(47.4) | |
| ORR | 8(22.9) | 2(5.3) | 0.023 |
| DCR | 27(77.1) | 20(52.6) | 0.002 |
Notes: Values are presented as the median (range) or n (%). P-value < 0.05 is statistically significant.
Abbreviations: CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; TBIL, total bilirubin; TNM, tumour-node-metastasis; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.